Lumoxiti

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Lumoxiti treats hairy cell leukemia (HCL). It is important for you to drink the additional prescribed amount of fluids (water, milk, or juice) as directed during Lumoxiti treatment.

Lumoxiti Overview

Reviewed: September 17, 2018
Updated: 

Lumoxiti is a prescription medication used to treat adult patients with hairy cell leukemia (HCL) that came back or did not get better with at least two other systemic treatments. Lumoxiti contains a monoclonal antibody called moxetumomab that binds to a protein called CD22, which is found on B cells (a type of white blood cell) and some types of leukemia cells. It also contains a bacterial toxin called PE38, which may help kill cancer cells. Lumoxiti is a type of immunotoxin.

This medication comes in an injectable form to be given directly into a vein (IV) by a healthcare professional. Lumoxiti is usually given on Day 1, Day 3, and Day 5 of a 28-day treatment cycle. You may receive up to 6 treatment cycles.

Common side effects of Lumoxiti include swelling, nausea and tiredness.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Lumoxiti Drug Class

Back to Top

Lumoxiti is part of the drug class:

Lumoxiti FDA Warning

Back to Top

WARNING: CAPILLARY LEAK SYNDROME AND HEMOLYTIC UREMIC SYNDROME 

  • Capillary Leak Syndrome (CLS), including life-threatening cases, occurred in patients receiving Lumoxiti. Monitor weight and blood pressure; check labs, including albumin, if CLS is suspected. Delay dosing or discontinue Lumoxiti as recommended.
  • Hemolytic Uremic Syndrome (HUS), including life-threatening cases, occurred in patients receiving Lumoxiti. Monitor hemoglobin, platelet count, serum creatinine, and ensure adequate hydration. Discontinue Lumoxiti in patients with Hemolytic Uremic Syndrome (HUS).